PMID: identifiant
de la référence Pubmed : |
 |
 (21330328)  |
|
| titre : |
|
Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells. |
|
| auteur(s) : |
|
Li Wang1, 2, Wen-Yu Shi1, Fan Yang1, 2, Wei Tang1, Guillaume Gapihan2, 3, 4, Mariana Varna2, 3, 4, Zhi-Xiang Shen1, Sai-Juan Chen1, 2, Christophe Leboeuf2, 3, 4, Anne Janin ( ) 2, 3, 4, Wei-Li Zhao () 1, 2 |
|
| laboratoire : |
|
|
|
| résumé : |
|
Vascular endothelial growth factor-A, an angiogenesis stimulator expressed on both tumor endothelial and malignant T cells, is involved in tumor progression in T-leukemia/lymphoma. Here, we assessed the impact of therapeutic vascular endothelial growth factor-A blockade on tumor-endothelial cell interaction and on tumor progression. In a murine xenograft T-leukemia/lymphoma model, combined bevacizumab (monoclonal antibody against vascular endothelial growth factor-A) with doxorubicin, compared with doxorubicin alone, significantly delayed tumor growth and induced prevalence of tumor cell apoptosis over mitosis. More importantly, the combined treatment induced endothelial cell swelling, microvessel occlusions, and tumor necrosis. In vitro, co-culture of endothelial cells with T-leukemia/lymphoma cells showed that doxorubicin induced expression of intracellular cell adhesion molecule-1, provided endothelial and malignant T cells were in direct contact. This was abrogated by bevacizumab treatment with doxorubicin. Taken together, bevacizumab enhances the chemotherapeutic effect on T-leukemia/lymphoma cells. Directly targeting tumor endothelial cells might be a promising therapeutic strategy to counteract tumor progression in T-cell malignancies. |
|
| domaine : |
|
Sciences du Vivant/Cancérologie
|
|
langue du texte
intégral : |
|
Anglais |
|
| ISSN : |
|
0390-6078 |
|
|
| type de publication : |
|
Articles dans des revues avec comité de lecture |
|
| DOI : |
|
10.3324/haematol.2010.037689 |
|
| journal : |
|
| Haematologica (Haematologica) |
| Publisher |
Ferrata Storti Foundation |
| ISSN |
0390-6078 (eISSN : 1592-8721) |
|
|
| Audience : |
|
internationale |
|
| date de publication : |
|
06/2011 |
|
date de publication
électronique : |
|
17/02/2011 |
|
| volume : |
|
96 |
|
| numéro : |
|
6 |
|
| page, identifiant, ... : |
|
927-31 |
|
|
| mots-clés auteur : |
|
T-cell leukemia/lymphoma – bevacizumab – endothelial cells |
|
| Descripteur(s) MeSH : |
|
Angiogenesis Inhibitors – Animals – Antibodies – Monoclonal – Humanized – Antineoplastic Agents – Apoptosis – Cell Line – Tumor – Down-Regulation – Endothelial Cells – Humans – Intercellular Adhesion Molecule-1 – Jurkat Cells – Leukemia – T-Cell – Lymphoma – Mice – Nude – Neovascularization – Pathologic – Tumor Burden – Vascular Endothelial Growth Factor A – Xenograft Model Antitumor Assays |
|
